{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000083","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.957650+00:00","generated_at":"2026-06-24T03:25:18.153198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track","bullets":["Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.","Cash $427M as of June 30; expects runway into calendar 2025 despite $31M in CMC/clinical payments in Q1.","Pivotal batoclimab trial in Myasthenia Gravis initiated June 2022; top-line data expected H2 2024.","FDA alignment on two pivotal trials in Thyroid Eye Disease; trials to start H2 2022, data H1 2025.","Investor call Sep 7 to announce two new batoclimab indications and third pivotal trial for 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000083","json":"https://secwatch.observer/filing/0001764013-22-000083.json","markdown":"https://secwatch.observer/filing/0001764013-22-000083.md","text":"https://secwatch.observer/filing/0001764013-22-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000083/0001764013-22-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000083/imvt-20220805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:25:18.153198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}